vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Proto Labs Inc的1.3倍（$183.1M vs $139.3M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 5.8%，领先7.5%），Proto Labs Inc同比增速更快（10.4% vs -1.8%），过去两年Proto Labs Inc的营收复合增速更高（5.3% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
AMPH vs PRLB — 直观对比
营收规模更大
AMPH
是对方的1.3倍
$139.3M
营收增速更快
PRLB
高出12.2%
-1.8%
净利率更高
AMPH
高出7.5%
5.8%
两年增速更快
PRLB
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $139.3M |
| 净利润 | $24.4M | $8.1M |
| 毛利率 | 46.8% | 45.6% |
| 营业利润率 | 19.4% | 7.1% |
| 净利率 | 13.3% | 5.8% |
| 营收同比 | -1.8% | 10.4% |
| 净利润同比 | -35.7% | 125.4% |
| 每股收益（稀释后） | $0.51 | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPRLB
| Q1 26 | — | $139.3M | ||
| Q4 25 | $183.1M | $136.5M | ||
| Q3 25 | $191.8M | $135.4M | ||
| Q2 25 | $174.4M | $135.1M | ||
| Q1 25 | $170.5M | $126.2M | ||
| Q4 24 | $186.5M | $121.8M | ||
| Q3 24 | $191.2M | $125.6M | ||
| Q2 24 | $182.4M | $125.6M |
净利润AMPHPRLB
| Q1 26 | — | $8.1M | ||
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $7.2M | ||
| Q2 25 | $31.0M | $4.4M | ||
| Q1 25 | $25.3M | $3.6M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $7.2M | ||
| Q2 24 | $37.9M | $4.5M |
毛利率AMPHPRLB
| Q1 26 | — | 45.6% | ||
| Q4 25 | 46.8% | 44.2% | ||
| Q3 25 | 51.4% | 45.3% | ||
| Q2 25 | 49.6% | 44.3% | ||
| Q1 25 | 50.0% | 44.1% | ||
| Q4 24 | 46.5% | 42.7% | ||
| Q3 24 | 53.3% | 45.6% | ||
| Q2 24 | 52.2% | 45.0% |
营业利润率AMPHPRLB
| Q1 26 | — | 7.1% | ||
| Q4 25 | 19.4% | 5.0% | ||
| Q3 25 | 13.2% | 6.5% | ||
| Q2 25 | 24.2% | 3.7% | ||
| Q1 25 | 21.9% | 3.6% | ||
| Q4 24 | 24.2% | -1.2% | ||
| Q3 24 | 29.8% | 6.8% | ||
| Q2 24 | 30.3% | 4.8% |
净利率AMPHPRLB
| Q1 26 | — | 5.8% | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 5.3% | ||
| Q2 25 | 17.8% | 3.3% | ||
| Q1 25 | 14.8% | 2.9% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 5.7% | ||
| Q2 24 | 20.8% | 3.6% |
每股收益（稀释后）AMPHPRLB
| Q1 26 | — | $0.29 | ||
| Q4 25 | $0.51 | $0.25 | ||
| Q3 25 | $0.37 | $0.30 | ||
| Q2 25 | $0.64 | $0.18 | ||
| Q1 25 | $0.51 | $0.15 | ||
| Q4 24 | $0.74 | $-0.01 | ||
| Q3 24 | $0.78 | $0.29 | ||
| Q2 24 | $0.73 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $124.0M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $683.1M |
| 总资产 | $1.6B | $778.6M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHPRLB
| Q1 26 | — | $124.0M | ||
| Q4 25 | $282.8M | $128.1M | ||
| Q3 25 | $276.2M | $119.2M | ||
| Q2 25 | $231.8M | $103.2M | ||
| Q1 25 | $236.9M | $96.8M | ||
| Q4 24 | $221.6M | $103.1M | ||
| Q3 24 | $250.5M | $100.5M | ||
| Q2 24 | $217.8M | $112.9M |
总债务AMPHPRLB
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHPRLB
| Q1 26 | — | $683.1M | ||
| Q4 25 | $788.8M | $673.9M | ||
| Q3 25 | $776.7M | $664.7M | ||
| Q2 25 | $757.5M | $664.7M | ||
| Q1 25 | $751.3M | $656.8M | ||
| Q4 24 | $732.3M | $670.2M | ||
| Q3 24 | $727.7M | $680.0M | ||
| Q2 24 | $713.3M | $685.2M |
总资产AMPHPRLB
| Q1 26 | — | $778.6M | ||
| Q4 25 | $1.6B | $763.4M | ||
| Q3 25 | $1.7B | $756.9M | ||
| Q2 25 | $1.6B | $743.3M | ||
| Q1 25 | $1.6B | $737.5M | ||
| Q4 24 | $1.6B | $743.5M | ||
| Q3 24 | $1.5B | $753.8M | ||
| Q2 24 | $1.5B | $758.2M |
负债/权益比AMPHPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $17.5M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | 2.16× |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHPRLB
| Q1 26 | — | $17.5M | ||
| Q4 25 | $32.9M | $16.5M | ||
| Q3 25 | $52.6M | $29.1M | ||
| Q2 25 | $35.6M | $10.6M | ||
| Q1 25 | $35.1M | $18.4M | ||
| Q4 24 | $29.0M | $17.3M | ||
| Q3 24 | $60.0M | $24.8M | ||
| Q2 24 | $69.1M | $14.4M |
自由现金流AMPHPRLB
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $8.4M | ||
| Q3 25 | $47.2M | $25.0M | ||
| Q2 25 | $25.0M | $9.1M | ||
| Q1 25 | $24.4M | $17.1M | ||
| Q4 24 | $16.6M | $16.5M | ||
| Q3 24 | $46.2M | $23.2M | ||
| Q2 24 | $63.1M | $10.2M |
自由现金流率AMPHPRLB
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 6.2% | ||
| Q3 25 | 24.6% | 18.5% | ||
| Q2 25 | 14.3% | 6.7% | ||
| Q1 25 | 14.3% | 13.6% | ||
| Q4 24 | 8.9% | 13.5% | ||
| Q3 24 | 24.1% | 18.5% | ||
| Q2 24 | 34.6% | 8.2% |
资本支出强度AMPHPRLB
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 5.9% | ||
| Q3 25 | 2.8% | 3.0% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 1.0% | ||
| Q4 24 | 6.7% | 0.7% | ||
| Q3 24 | 7.2% | 1.2% | ||
| Q2 24 | 3.3% | 3.3% |
现金转化率AMPHPRLB
| Q1 26 | — | 2.16× | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 4.03× | ||
| Q2 25 | 1.15× | 2.39× | ||
| Q1 25 | 1.39× | 5.11× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 3.44× | ||
| Q2 24 | 1.82× | 3.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
